Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 19

CN76 - Cost effectiveness of high versus low-to-moderate intensity exercise during oncological treatment: The Phys-Can RCT

Date

10 Sep 2022

Session

Poster session 19

Topics

Cancer Care Equity Principles and Health Economics

Tumour Site

Presenters

Anna-karin Ax

Citation

Annals of Oncology (2022) 33 (suppl_7): S827-S836. 10.1016/annonc/annonc1046

Authors

A. Ax1, M. Husberg2, B.B. Johansson3, I. Demmelmaier4, S. Berntsen5, K. Sjövall6, S. Börjeson7, K. Nordin8, T. Davidson9

Author affiliations

  • 1 Department Of Health, Medicine And Caring Sciences, LiU - Linkoping University, 581 83 - Linköping/SE
  • 2 Department Of Health, Medicine And Caring Sciences, Linköping University, Linköping/SE
  • 3 Immunology, Genetics And Pathology, Uppsala University - Rudbecklaboratoriet, 752 37 - Uppsala/SE
  • 4 Department Of Public Health And Caring Sciences, Uppsala University, 75105 - Uppsala/SE
  • 5 Department Of Sport Science And Physical Education, University of Agder, 4604 - Kristiansand/NO
  • 6 Department Of Department Of Oncology, Faculty Of Health Sciences, Kristianstad University, 29188 - Kristianstad/SE
  • 7 Epartment Of Health, Medicine And Caring Sciences, Linköping University, Linköping/SE
  • 8 Department Of Public Health And Caring Sciences, Uppsala University, 752 37 - Uppsala/SE
  • 9 Department Of Health, Medicine And Caring Sciences, Linköping University, 581 83 - Linköping/SE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract CN76

Background

A cost-effectiveness analysis, considering both costs and health outcomes of interventions, are important for decision-making and implementation in the health care. Exercise during oncological treatment is beneficial for health and have been found to counteract side effects of treatment. The Swedish Phys-Can RCT compared a six-month exercise program combining supervised resistance training and homebased endurance training of high-intensity (HI) versus low-to-moderate intensity (LMI), with or without additional behaviour change support. At post intervention, HI yielded small improvements of fitness and physical fatigue compared with LMI. At 18 months, no differences were found in total costs between the intensities. However, knowledge of the cost effectiveness in exercise interventions with regard to intensity is limited. In this study, we aimed to evaluate the long-term cost-effectiveness of an exercise program at HI versus LMI during oncological treatment.

Methods

A cost-effectiveness analysis was undertaken from a societal perspective for 18 months. 189 (n=99 HI and n=90 LMI) participants with breast, colorectal, or prostate cancer were included from the Phys-Can RCT. Health outcomes were measured as quality-adjusted life years (QALYs), using EQ-5D-5L at baseline, six months and 18 months. Costs included the exercise intervention, health care utilisation and productivity loss.

Results

At 18 months, the total cost per participant did not differ significantly between HI (€27,314) and LMI exercise (€29,788). There was no significant difference in health outcome between the intensities. On average HI generated 1.190 (SD = 0.223) QALYs and LMI 1.185 (SD = 0.211) QALYs for 18 months, meaning HI led to an additional 0.005 QALYs. The incremental cost-effectiveness ratio (ICER) indicates that HI was more effective and saved costs compared with LMI.

Conclusions

The uncertainty around the ICER was large, however our results indicates that HI exercise was cost-effective compared to LMI exercise at longer term since there was lower total costs per QALY gained. Thus, we suggest that exercise with its health benefits may be implemented regardless of intensity.

Clinical trial identification

NCT02473003.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

The Swedish Research Council the Swedish Research Council, Region Östergötland and the Swedish cancer society.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.